TCGA-58-A46M-01A-11R-A24H-07
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 61
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.620
- MYC_TARGETS_V2+0.580
- G2M_CHECKPOINT+0.560
- MYC_TARGETS_V1+0.530
- INTERFERON_ALPHA_RESPONSE+0.520
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.390
- UNFOLDED_PROTEIN_RESPONSE+0.390
- OXIDATIVE_PHOSPHORYLATION+0.350
- DNA_REPAIR+0.340
- INTERFERON_GAMMA_RESPONSE+0.340
Top 10 suppressed
- ANGIOGENESIS-0.540
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.450
- COAGULATION-0.420
- TGF_BETA_SIGNALING-0.380
- KRAS_SIGNALING_UP-0.360
- MYOGENESIS-0.340
- ESTROGEN_RESPONSE_EARLY-0.330
- APICAL_JUNCTION-0.320
- HYPOXIA-0.320
- TNFA_SIGNALING_VIA_NFKB-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8613729 | — | E | 0.918 |
| 2 | SRR8518323 | — | E | 0.896 |
| 3 | SRR650180 | — | — | 0.887 |
| 4 | SRR8518219 | — | E | 0.886 |
| 5 | s0112318 | — | — | 0.885 |
| 6 | 504282dd-4fef-4f70-a709-6a545d00a263 | — | — | 0.885 |
| 7 | 20020093.Her2HRneg | — | E | 0.883 |
| 8 | TCGA-21-1083-01A-01R-0692-07 | — | cohortMD1 | 0.882 |
| 9 | SRR8518168 | — | E | 0.877 |
| 10 | SRR6013511 | — | cohortSQ1 | 0.870 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.620 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.580 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.560 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.530 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.520 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.390 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.390 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.350 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.340 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.340 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.330 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.230 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.230 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.180 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.160 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.060 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.040 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.020 | Idelalisib | — uncovered |